Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Instagram Outage Disrupts Thousands of U.S. Users 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
OXFORD, United Kingdom, Sept. 05, 2016 -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be announcing its financial results for the second quarter and half year ended 31 July 2016 on Thursday, 8 September 2016.
Summit will host a conference call the same day at 1:00pm BST / 8:00am EDT. Conference call information will be included in the half year results press release and a replay of the call will also be available through the Company's website, www.summitplc.com.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease DMD and the infectious disease Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
| Summit Therapeutics | ||
| Glyn Edwards / Richard Pye (UK office) | Tel: +44 (0)1235 443 951 | |
| Erik Ostrowski / Michelle Avery (US office) | +1 617 225 4455 | |
| Cairn Financial Advisers LLP | ||
| (Nominated Adviser) | ||
| Liam Murray / Tony Rawlinson | Tel: +44 (0)20 7148 7900 | |
| N+1 Singer | ||
| (Broker) | ||
| Aubrey Powell / Jen Boorer | Tel: +44 (0)20 7496 3000 | |
| MacDougall Biomedical Communications | ||
| (US media contact) | Tel: +1 781 235 3060 | |
| Chris Erdman / Karen Sharma | [email protected] / | |
| [email protected] | ||
| Consilium Strategic Communications | ||
| (Financial public relations, UK) | Tel: +44 (0)20 3709 5700 | |
| Mary-Jane Elliott / Sue Stuart / | [email protected] | |
| Jessica Hodgson / Lindsey Neville |
